de new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the […]
Original article: Acclaim-3 Dosing Begins: Quaratusugene Ozeplasmid/Atezolizumab in ES-SCLC (Targeted Oncology)
Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024
Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors
Ryan Confer Appointed Genprex President and CEO and to its Board of Directors
AUSTIN, Texas — (May. 1, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company’s participation in the following upcoming investor and industry conferences to be held in May 2024. Event: Sidoti Microcap Conference Conference Dates: May 8-9, 2024 […]